SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med. 2004; 351: 1860-1873.
  • 2
    Kyle RA, Remstein ED, Therneau TM, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med. 2007; 356: 2582-2590.
  • 3
    Bladé J, Dimopoulos M, Rosiñol L, et al. Smoldering (asymptomatic) multiple myeloma: current diagnostic criteria, new predictors of outcome, and follow-up recommendations. J Clin Oncol. 2010; 28: 690-697.
  • 4
    Kyle RA, Durie BG, Rajkumar SV, et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia. 2011; 24: 1121-1127.
  • 5
    Rajkumar SV, Kyle RA, Therneau TM, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood. 2005; 106: 812-817.
  • 6
    Dispenzieri A, Kyle RA, Katzmann JA, et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood. 2008; 111: 785-789.
  • 7
    Hjorth M, Hellquist L, Holmberg E, Magnusson B, Rödjer S, Westin J. Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I–a randomized study. Myeloma Group of Western Sweden. Eur J Haematol. 1993; 50: 95-102.
  • 8
    Korde N, Kristinsson SY, Landgren O. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies. Blood. 2011; 117: 5573-5581.
  • 9
    Landgren O, Kyle RA, Rajkumar SV. From myeloma precursor disease to multiple myeloma: new diagnostic concepts and opportunities for early intervention. Clin Cancer Res. 2011; 17: 1243-1252.
  • 10
    Musto P, Petrucci MT, Bringhen S, et al. A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma. Cancer. 2008; 113: 1588-1595.
    Direct Link:
  • 11
    Rajkumar SV, Dispenzieri A, Fonseca R, et al. Thalidomide for previously untreated indolent or smoldering multiple myeloma. Leukemia. 2001; 15: 1274-1276.
  • 12
    Barlogie B, van Rhee F, Shaughnessy JDJr, et al. Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease. Blood. 2008; 112: 3122-3125.
  • 13
    Rajkumar SV, Larson D, Kyle RA. Diagnosis of smoldering multiple myeloma. N Engl J Med. 2011; 365: 474-475.
  • 14
    Hintze J. NCSS, PASS, and GESS [computer program]. Kaysville, UT: NCSS, LLC; 2007.
  • 15
    Saez B, Martin-Subero JI, Guillen-Grima F, et al. Chromosomal abnormalities clustering in multiple myeloma reveals cytogenetic subgroups with non random acquisition of chromosomal changes. Leukemia. 2004; 18: 654-657.
  • 16
    Zhan F, Barlogie B, Arzoumanian V, et al. Gene expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood. 2007; 109: 1692-1700.
  • 17
    Rosiñol L, Carrié A, Bladé J, et al. Comparative genomic hybridisation identifies two variants of smoldering multiple myeloma. Br J Haematol. 2005; 130: 729-732.
  • 18
    Dispenzieri A, Kyle RA, Katzmann JA, et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood. 2008; 111: 785-789.
  • 19
    Pérez-Persona E, Vidriales MB, Mateo G, et al. New criteria to identify risk of progression in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood. 2007; 110: 2586-2592.
  • 20
    Pérez-Persona E, Mateo G, García-Sanz R, et al. Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells. Br J Haematol. 2010; 148: 110-114.
  • 21
    Rosiñol L, Bladè J, Esteve J, et al. Smoldering multiple myeloma: natural history and recognition of an evolving type. Br J Haematol. 2003; 123: 631-636.
  • 22
    Terpstra WE, Lokhorst HM, Blomjous F, et al. Comparison of plasma cell infiltration in bone marrow biopsies and aspirates in patients with multiple myeloma. Br J Haematol. 1992; 82: 46-49.
  • 23
    Chilosi M, Adami F, Lestani M. CD 138/syndecan-1: a useful immunohistochemical marker of normal and neoplastic plasma cells on routine trephine bone marrow biopsies. Mod Pathol. 1999; 12: 1101-1106.